VivoSeq
Other

Cesarean Section

165

Pipeline Programs

40

Active Trials

45

Companies Involved

Cesarean Section is a highly competitive landscape with 165 programs across 45 companies. The most active players are Edison Pharmaceuticals Inc, Javelin Pharmaceuticals, Milestone Pharmaceuticals Inc.. 62 therapies are approved with 22 more in late-stage development.

Pipeline Metrics

Competitive Density

78/100

Pipeline Velocity

43/100

Mech. Concentration

12/100

Completion Rate

89/100

Attrition Rate

8/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

100%

Small molecule

222 of 223 classified programs — the dominant modality here.

0%ALL OTHERSProtein / enzyme1<1%

Small molecule leads; the ring shows all 223 classified programs, each share of the total. Modality classified for 100% of 231 pipeline programs.

Trial Status

304

clinical trials

Completed179 · 59%
Unknown status61 · 20%
Recruiting21 · 7%
Not yet recruiting16 · 5%
Terminated16 · 5%
Withdrawn7 · 2%
Other4 · 1%

Trial Activity

304 trials

Dexmedetomidine Wound Infiltration in Cesarean Section
Recruiting··N/A·NCT03382938·100 enrolled
Chloroprocaine 1% Versus Ropivacaine 0,75% During Cesarean Section
Recruiting··N/A·NCT06376058·60 enrolled
Page 1 of 21

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)